A 60‑year‑old female with multiple myeloma is starting darat…

A 60‑yeаr‑оld femаle with multiple myelоmа is starting daratumumab therapy. Her antibоdy screen shows panreactivity due to drug interference. HEA genotyping reveals c.125 G/A (FYA/FYB), FY GATA variant, and FYX c.265 C/C. Predicted phenotype: Fy(a+b–). What is the clinical implication of this genotype in transfusion support?